WHO ICTRP trial
A multicenter, prospective, observational cohort study comparing lenvatinib…
ChiCTR2600117082 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600117082 |
|---|---|
| Public title | A multicenter, prospective, observational cohort study comparing lenvatinib mesylate and tislelizumab in combination with RALOX-HAIC versus combination with FOLFOX-HAIC for the treatment of advanced hepatocellular carcinoma |
| Scientific title | A multicenter, prospective, observational cohort study comparing lenvatinib mesylate and tislelizumab in combination with RALOX-HAIC versus combination with FOLFOX-HAIC for the treatment of advanced hepatocellular carcinoma |
| Primary sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Countries | China |
| Conditions | Hepatocellular carcinoma |
| Interventions | FOLFOX-HAIC group (Hepatic Artery Infusion Chemotherapy):NA;RALOX-HAIC group (Hepatic Artery Infusion Chemotherapy):NA |
| Registration date | Jan 20, 2026 |
| Target size | FOLFOX-HAIC group (Hepatic Artery Infusion Chemotherapy):222;RALOX-HAIC group… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: